Characterization of a multi-component anthrax vaccine designed to target the initial stages of infection as well as toxaemia

Journal of Medical Microbiology

Volumn 61, Issue PART 10, 2012, Pages 1380-1392

  Cote, C K ^a   Kaatz, L ^a   Reinhardt, J ^a   Bozue, J ^a   Tobery, S A ^a   Bassett, A D ^a   Sanz, P ^b,c   Darnell, S C ^b   Alem, F ^b   O'Brien, A D ^b   Welkos, S L ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX VACCINE; BACTERIAL ANTIGEN; BCLA ANTIGEN; EPITOPE; EXSFA ANTIGEN; P5303 ANTIGEN; PROTECTIVE ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTHRAX; ARTICLE; BACILLUS ANTHRACIS; BACTERIAL SPORE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; FEMALE; GUINEA PIG; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; TOXEMIA;

ANIMALS; ANTHRAX; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; ANTIGENS, SURFACE; BACILLUS ANTHRACIS; BACTERIAL VACCINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GUINEA PIGS; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; RABBITS; SPORES, BACTERIAL; TOXEMIA;

EID: 84866413110     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/jmm.0.045393-0     Document Type: Article

References (64)

1. Baillie, L., Townend, T., Walker, N., Eriksson, U. & Williamson, D. (2004). Characterization of the human immune response to the UK anthrax vaccine. FEMS Immunol Med Microbiol 42, 267-270.
2. Basu, S., Kang, T. J., Chen, W. H., Fenton, M. J., Baillie, L., Hibbs, S. & Cross, A. S. (2007). Role of Bacillus anthracis spore structures in macrophage cytokine responses. Infect Immun 75, 2351-2358.
3. Beedham, R. J., Turnbull, P. C. & Williamson, E. D. (2001). Passive transfer of protection against Bacillus anthracis infection in a murine model. Vaccine 19, 4409-4416.
4. Bielinska, A. U., Janczak, K. W., Landers, J. J., Makidon, P., Sower, L. E., Peterson, J. W. & Baker, J. R., Jr (2007). Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge. Infect Immun 75, 4020-4029.
5. Boyaka, P. N., Tafaro, A., Fischer, R., Leppla, S. H., Fujihashi, K. & McGhee, J. R. (2003). Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen. J Immunol 170, 5636-5643.
6. Bozue, J., Cote, C. K., Moody, K. L. & Welkos, S. L. (2007a). Fully virulent Bacillus anthracis does not require the immunodominant protein BclA for pathogenesis. Infect Immun 75, 508-511.
7. Bozue, J., Moody, K. L., Cote, C. K., Stiles, B. G., Friedlander, A. M., Welkos, S. L. & Hale, M. L. (2007b). Bacillus anthracis spores of the bclA mutant exhibit increased adherence to epithelial cells, fibroblasts, and endothelial cells but not to macrophages. Infect Immun 75, 4498-4505.
8. Brahmbhatt, T. N., Darnell, S. C., Carvalho, H. M., Sanz, P., Kang, T. J., Bull, R. L., Rasmussen, S. B., Cross, A. S. & O'Brien, A. D. (2007). Recombinant exosporium protein BclA of Bacillus anthracis is effective as a booster for mice primed with suboptimal amounts of protective antigen. Infect Immun 75, 5240-5247.
9. Brossier, F., Levy, M. & Mock, M. (2002). Anthrax spores make an essential contribution to vaccine efficacy. Infect Immun 70, 661-664.
10. Cote, C. K., Rossi, C. A., Kang, A. S., Morrow, P. R., Lee, J. S. & Welkos, S. L. (2005). The detection of protective antigen (PA) associated with spores of Bacillus anthracis and the effects of anti-PA antibodies on spore germination and macrophage interactions. Microb Pathog 38, 209-225.
11. Cote, C. K., Van Rooijen, N. & Welkos, S. L. (2006). Roles of macrophages and neutrophils in the early host response to Bacillus anthracis spores in a mouse model of infection. Infect Immun 74, 469-480.
12. Cote, C. K., Bozue, J., Moody, K. L., DiMezzo, T. L., Chapman, C. E. & Welkos, S. L. (2008). Analysis of a novel spore antigen in Bacillus anthracis that contributes to spore opsonization. Microbiology 154, 619-632.
13. Cote, C. K., Bozue, J., Twenhafel, N. & Welkos, S. L. (2009). Effects of altering the germination potential of Bacillus anthracis spores by exogenous means in a mouse model. J Med Microbiol 58, 816-825.
14. Cote, C. K., Welkos, S. L. & Bozue, J. (2011). Key aspects of the molecular and cellular basis of inhalational anthrax. Microbes Infect 13, 1146-1155.
15. Cybulski, R. J., Jr, Sanz, P., McDaniel, D., Darnell, S., Bull, R. L. & O'Brien, A. D. (2008). Recombinant Bacillus anthracis spore proteins enhance protection of mice primed with suboptimal amounts of protective antigen. Vaccine 26, 4927-4939.
16. Dixon, T. C., Meselson, M., Guillemin, J. & Hanna, P. C. (1999). Anthrax. N Engl J Med 341, 815-826.
17. Enkhtuya, J., Kawamoto, K., Kobayashi, Y., Uchida, I., Rana, N. & Makino, S. (2006). Significant passive protective effect against anthrax by antibody to Bacillus anthracis inactivated spores that lack two virulence plasmids. Microbiology 152, 3103-3110.
18. Flick-Smith, H. C., Waters, E. L., Walker, N. J., Miller, J., Stagg, A. J., Green, M. & Williamson, E. D. (2005). Mouse model characterisation for anthrax vaccine development: comparison of one inbred and one outbred mouse strain. Microb Pathog 38, 33-40.
19. Fox, C. B. (2009). Squalene emulsions for parenteral vaccine and drug delivery. Molecules 14, 3286-3312.
20. Friedlander, A. M. (1999). Clinical aspects, diagnosis and treatment of anthrax. J Appl Microbiol 87, 303.
21. Friedlander, A. M. (2000). Anthrax: clinical features, pathogenesis, and potential biological warfare threat. Curr Clin Top Infect Dis 20, 335-349.
22. Friedlander, A. M., Pittman, P. R. & Parker, G. W. (1999). Anthrax vaccine: evidence for safety and efficacy against inhalational anthrax. JAMA 282, 2104-2106.
23. Gauthier, Y. P., Tournier, J. N., Paucod, J. C., Corre, J. P., Mock, M., Goossens, P. L. & Vidal, D. R. (2009). Efficacy of a vaccine based on protective antigen and killed spores against experimental inhalational anthrax. Infect Immun 77, 1197-1207.
24. Glomski, I. J., Corre, J. P., Mock, M. & Goossens, P. L. (2007a). Cutting edge: IFN-c-producing CD4 T lymphocytes mediate sporeinduced immunity to capsulated Bacillus anthracis. J Immunol 178, 2646-2650.
25. Glomski, I. J., Piris-Gimenez, A., Huerre, M., Mock, M. & Goossens, P. L. (2007b). Primary involvement of pharynx and Peyer's patch in inhalational and intestinal anthrax. PLoS Pathog 3, e76.
26. Goossens, P. L., Sylvestre, P. & Mock, M. (2007). Of spore opsonization and passive protection against anthrax. Microbiology 153, 301-302, discussion 302-304.
27. Hahn, U. K., Boehm, R. & Beyer, W. (2006). DNA vaccination against anthrax in mice-combination of anti-spore and anti-toxin components. Vaccine 24, 4569-4571.
28. Heine, H. S., Bassett, J., Miller, L., Hartings, J. M., Ivins, B. E., Pitt, M. L., Fritz, D., Norris, S. L. & Byrne, W. R. (2007). Determination of antibiotic efficacy against Bacillus anthracis in a mouse aerosol challenge model. Antimicrob Agents Chemother 51, 1373-1379.
29. Heninger, S., Drysdale, M., Lovchik, J., Hutt, J., Lipscomb, M. F., Koehler, T. M. & Lyons, C. R. (2006). Toxin-deficient mutants of Bacillus anthracis are lethal in a murine model for pulmonary anthrax. Infect Immun 74, 6067-6074.
30. Kudva, I. T., Griffin, R. W., Garren, J. M., Calderwood, S. B. & John, M. (2005). Identification of a protein subset of the anthrax spore immunome in humans immunized with the anthrax vaccine adsorbed preparation. Infect Immun 73, 5685-5696.
31. Little, S. F., Ivins, B. E., Fellows, P. F., Pitt, M. L., Norris, S. L. & Andrews, G. P. (2004). Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine. Vaccine 22, 422-430.
32. Lyons, C. R., Lovchik, J., Hutt, J., Lipscomb, M. F., Wang, E., Heninger, S., Berliba, L. & Garrison, K. (2004). Murine model of pulmonary anthrax: kinetics of dissemination, histopathology, and mouse strain susceptibility. Infect Immun 72, 4801-4809.
33. Mikesell, P., Ivins, B. E., Ristroph, J. D. & Dreier, T. M. (1983). Evidence for plasmid-mediated toxin production in Bacillus anthracis. Infect Immun 39, 371-376.
34. Mock, M. & Fouet, A. (2001). Anthrax. Annu Rev Microbiol 55, 647-671.
35. Moody, K. L., Driks, A., Rother, G. L., Cote, C. K., Brueggemann, E. E., Hines, H. B., Friedlander, A. M. & Bozue, J. (2010). Processing, assembly and localization of a Bacillus anthracis spore protein. Microbiology 156, 174-183.
36. Oliva, C. R., Swiecki, M. K., Griguer, C. E., Lisanby, M. W., Bullard, D. C., Turnbough, C. L., Jr & Kearney, J. F. (2008). The integrin Mac-1 (CR3) mediates internalization and directs Bacillus anthracis spores into professional phagocytes. Proc Natl Acad Sci U S A 105, 1261-1266.
37. Pickering, A. K., Osorio, M., Lee, G. M., Grippe, V. K., Bray, M. & Merkel, T. J. (2004). Cytokine response to infection with Bacillus anthracis spores. Infect Immun 72, 6382-6389.
38. Pitt, M. L. M., Little, S., Ivins, B. E., Fellows, P., Boles, J., Barth, J., Hewetson, J. & Friedlander, A. M. (1999). In vitro correlate of immunity in an animal model of inhalational anthrax. J Appl Microbiol 87, 304.
39. Popov, S. G., Popova, T. G., Grene, E., Klotz, F., Cardwell, J., Bradburne, C., Jama, Y., Maland, M., Wells, J. & other authors (2004). Systemic cytokine response in murine anthrax. Cell Microbiol 6, 225-233.
40. Powell, A. G., Crozier, J. E., Hodgson, H. & Galloway, D. J. (2011). A case of septicaemic anthrax in an intravenous drug user. BMC Infect Dis 11, 21.
41. Redmond, C., Baillie, L. W., Hibbs, S., Moir, A. J. & Moir, A. (2004). Identification of proteins in the exosporium of Bacillus anthracis. Microbiology 150, 355-363.
42. Ringertz, S. H., Høiby, E. A., Jensenius, M., Maehlen, J., Caugant, D. A., Myklebust, A. & Fossum, K. (2000). Injectional anthrax in a heroin skin-popper. Lancet 356, 1574-1575.
43. Ross, J. M. (1957). The pathogenesis of anthrax following the administration of spores by the respiratory route. J Pathol Bacteriol 73, 485-494.
44. Severson, K. M., Mallozzi, M., Bozue, J., Welkos, S. L., Cote, C. K., Knight, K. L. & Driks, A. (2009). Roles of the Bacillus anthracis spore protein ExsK in exosporium maturation and germination. J Bacteriol 191, 7587-7596.
45. Shivachandra, S. B., Li, Q., Peachman, K. K., Matyas, G. R., Leppla, S. H., Alving, C. R., Rao, M. & Rao, V. B. (2007). Multicomponent anthrax toxin display and delivery using bacteriophage T4. Vaccine 25, 1225-1235.
46. Shlyakhov, E. N. & Rubinstein, E. (1994). Human live anthrax vaccine in the former USSR. Vaccine 12, 727-730.
47. Steichen, C., Chen, P., Kearney, J. F. & Turnbough, C. L., Jr (2003). Identification of the immunodominant protein and other proteins of the Bacillus anthracis exosporium. J Bacteriol 185, 1903-1910.
48. Steichen, C. T., Kearney, J. F. & Turnbough, C. L., Jr (2005). Characterization of the exosporium basal layer protein BxpB of Bacillus anthracis. J Bacteriol 187, 5868-5876.
49. Sylvestre, P., Couture-Tosi, E. & Mock, M. (2002). A collagen-like surface glycoprotein is a structural component of the Bacillus anthracis exosporium. Mol Microbiol 45, 169-178.
50. Sylvestre, P., Couture-Tosi, E. & Mock, M. (2003). Polymorphism in the collagen-like region of the Bacillus anthracis BclA protein leads to variation in exosporium filament length. J Bacteriol 185, 1555-1563.
51. Sylvestre, P., Couture-Tosi, E. & Mock, M. (2005). Contribution of ExsFA and ExsFB proteins to the localization of BclA on the spore surface and to the stability of the Bacillus anthracis exosporium. J Bacteriol 187, 5122-5128.
52. Thompson, B. M., Hsieh, H.-Y., Spreng, K. A. & Stewart, G. C. (2011). The co-dependence of BxpB/ExsFA and BclA for proper incorporation into the exosporium of Bacillus anthracis. Mol Microbiol 79, 799-813.
53. Todd, S. J., Moir, A. J., Johnson, M. J. & Moir, A. (2003). Genes of Bacillus cereus and Bacillus anthracis encoding proteins of the exosporium. J Bacteriol 185, 3373-3378.
54. Turnbull, P. C. (1991). Anthrax vaccines: past, present and future. Vaccine 9, 533-539.
55. Turnbull, P. (2008). Anthrax in Humans and Animals, 4th edn. Geneva: WHO Press.
56. Vergis, J. M., Cote, C. K., Bozue, J., Alem, F., Ventura, C. L., Welkos, S. L. & O'Brien, A. D. (2011). Protection from challenge with B. anthracis Sterne or Ames after immunization with plasmid-cured B. cereus G9241 spores. In International Bacillus-ACT Meeting, p. 74, Bruges, Belgium.
57. Wasserman, G. M., Grabenstein, J. D., Pittman, P. R., Rubertone, M. V., Gibbs, P. P., Wang, L. Z. & Golder, L. G. (2003). Analysis of adverse events after anthrax immunization in US Army medical personnel. J Occup Environ Med 45, 222-233.
58. Welkos, S. L. & Friedlander, A. M. (1988). Comparative safety and efficacy against Bacillus anthracis of protective antigen and live vaccines in mice. Microb Pathog 5, 127-139.
59. Welkos, S. L., Keener, T. J. & Gibbs, P. H. (1986). Differences in susceptibility of inbred mice to Bacillus anthracis. Infect Immun 51, 795-800.
60. Welkos, S. L., Becker, D., Friedlander, A. & Trotter, R. (1989). Pathogenesis and host resistance to Bacillus anthracis: a mouse model. Salisbury Med Bull 68, 49-52.
61. Welkos, S. L., Vietri, N. J. & Gibbs, P. H. (1993). Non-toxigenic derivatives of the Ames strain of Bacillus anthracis are fully virulent for mice: role of plasmid pX02 and chromosome in strain-dependent virulence. Microb Pathog 14, 381-388.
62. Welkos, S. L., Cote, C. K., Rea, K. M. & Gibbs, P. H. (2004). A microtiter fluorometric assay to detect the germination of Bacillus anthracis spores and the germination inhibitory effects of antibodies. J Microbiol Methods 56, 253-265.
63. Williamson, E. D., Hodgson, I., Walker, N. J., Topping, A. W., Duchars, M. G., Mott, J. M., Estep, J., Lebutt, C., Flick-Smith, H. C. & other authors (2005). Immunogenicity of recombinant protective antigen and efficacy against aerosol challenge with anthrax. Infect Immun 73, 5978-5987.
64. Young, J. A. & Collier, R. J. (2007). Anthrax toxin: receptor binding, internalization, pore formation, and translocation. Annu Rev Biochem 76, 243-265.